

**Mississippi Division Of Medicaid**  
**Provider Notice of Preferred Drug List Changes**  
**P&T Meeting Date: August 9, 2022**  
**PDL Changes Effective Date: October 1, 2022**



The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2022, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

<b>NEW PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for PREFERRED STATUS</b>
ANTIRETROVIRALS	APRETUDE ER (cabotegravir)
ATOPIC DERMATITIS	ADBRY (tralokinumab)

<b>NEW NON-PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
ACNE AGENTS, RETINOIDS	TWYNEO (tretinoin/benzoyl peroxide)
ANDROGENIC AGENTS	TLANDO (testosterone)
ANTICONVULSANTS	EPRONTIA (topiramate solution)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	SCSEMBLIX (asciminib)
ANTIVIRAL, CMV	LIVTENCITY (maribavir)
ATOPIC DERMATITIS	CIBINQO (abrocitinib)
COLONY STIMULATING FACTOR	RELEUKO (filgrastim)
GI ULCER THERAPY	DARTISLA ODT (glycopyrrolate)
GROWTH HORMONE	SKYTROFA (lonapegsomatropin)
GROWTH HORMONE	VOXZOGO (vosoritide)
IMMUNOLOGIC THERAPIES FOR ASTHMA	TEZSPIRE (tezepelumab)
IRRITABLE BOWEL SYNDROME, CONSTIPATION	IBSRELA (tenapanor)
LIPOTROPIC, NON-STATIN	LEQVIO (inclisiran)
NSAIDS	ELYXYB (celecoxib)
NSAIDS	LOFENA (diclofenac potassium)

**Mississippi Division Of Medicaid**  
**Provider Notice of Preferred Drug List Changes**  
**P&T Meeting Date: August 9, 2022**  
**PDL Changes Effective Date: October 1, 2022**



<b>NEW NON-PREFERRED DRUGS</b>	
<b>THERAPEUTIC CLASS</b>	<b>RECOMMENDED for NON-PREFERRED STATUS</b>
OPIATE DEPENDENCY TREATMENT	ZIMHI (naloxone)
OPIOID, COMBINATIONS	SEGLENTIS (tramadol/celecoxib)
SEDATIVE HYPNOTICS, OTHER	QUVIVIQ (daridorexant)
SKELETAL MUSCLE RELAXANTS	FLEQSUVY (baclofen liquid)